BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 23468082)

  • 1. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.
    Kim DH; Kwak Y; Kim ND; Sim T
    Cancer Biol Ther; 2016; 17(1):65-78. PubMed ID: 26574622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.
    Squillace RM; Miller D; Wardwell SD; Wang F; Clackson T; Rivera VM
    Int J Oncol; 2012 Aug; 41(2):425-32. PubMed ID: 22614157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models.
    Squillace RM; Miller D; Cookson M; Wardwell SD; Moran L; Clapham D; Wang F; Clackson T; Rivera VM
    Mol Cancer Ther; 2011 Oct; 10(10):1959-68. PubMed ID: 21825008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
    Packer LM; Geng X; Bonazzi VF; Ju RJ; Mahon CE; Cummings MC; Stephenson SA; Pollock PM
    Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O; Wackwitz B; Haus U; Ortmann O
    Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
    Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
    Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
    Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
    Korets SB; Musa F; Curtin J; Blank SV; Schneider RJ
    Gynecol Oncol; 2014 Feb; 132(2):468-73. PubMed ID: 24316308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates.
    Mazzoletti M; Bortolin F; Brunelli L; Pastorelli R; Di Giandomenico S; Erba E; Ubezio P; Broggini M
    Cancer Res; 2011 Jul; 71(13):4573-84. PubMed ID: 21602434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
    Berk L; Mita MM; Kreisberg J; Bedrosian CL; Tolcher AW; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2012 May; 69(5):1369-77. PubMed ID: 22231376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
    Chang KY; Tsai SY; Wu CM; Yen CJ; Chuang BF; Chang JY
    Clin Cancer Res; 2011 Nov; 17(22):7116-26. PubMed ID: 21976531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.
    Tsoref D; Welch S; Lau S; Biagi J; Tonkin K; Martin LA; Ellard S; Ghatage P; Elit L; Mackay HJ; Allo G; Tsao MS; Kamel-Reid S; Eisenhauer EA; Oza AM
    Gynecol Oncol; 2014 Nov; 135(2):184-9. PubMed ID: 25173583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.
    Taurin S; Yang CH; Reyes M; Cho S; Coombs DM; Jarboe EA; Werner TL; Peterson CM; Janát-Amsbury MM
    Int J Gynecol Cancer; 2018 Jan; 28(1):152-160. PubMed ID: 28953502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
    Hernandez SF; Chisholm S; Borger D; Foster R; Rueda BR; Growdon WB
    Gynecol Oncol; 2016 Jun; 141(3):570-579. PubMed ID: 27017985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.
    Eritja N; Domingo M; Dosil MA; Mirantes C; Santacana M; Valls J; Llombart-Cussac A; Matias-Guiu X; Dolcet X
    Mol Cancer Ther; 2014 Apr; 13(4):776-87. PubMed ID: 24448819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.
    Byron SA; Gartside MG; Wellens CL; Mallon MA; Keenan JB; Powell MA; Goodfellow PJ; Pollock PM
    Cancer Res; 2008 Sep; 68(17):6902-7. PubMed ID: 18757403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.